← Back to Screener
Hemab Therapeutics Holdings, Inc. Common Stock (COAG)
Price$27.81
All Metrics
Price vs S&P 500 (YTD)-29.06%
10-Day Avg Trading Volume0.91M
3-Month Avg Trading Volume0.91M
52-Week High$36.61
Year-to-Date Return-26.47%
5-Day Price Return0.00%
Month-to-Date Return-26.47%
52-Week Low$23.00
Industry Peers — Biological Products(90)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
COAGHemab Therapeutics Holdings, Inc. Common Stock | — | — | — | — | $27.81 |
| AMGNAmgen Inc | 4.80x | 9.07% | 73.95% | 2.93% | $334.72 |
| GILDGilead Sciences Inc | 5.72x | 3.48% | 79.35% | 133.64% | $132.91 |
| ARGXargenx SE American Depositary Shares | 10.79x | 80.59% | 144.51% | — | $800.15 |
| BIIBBiogen Inc. Common Stock | 2.99x | 1.23% | 75.49% | -18.77% | $199.79 |
| BNTXBioNTech SE American Depositary Share | 7.90x | -11.81% | 82.18% | — | $92.61 |
| MRNAModerna, Inc. Common Stock | 9.50x | -29.97% | 35.01% | — | $50.67 |
| NBIXNeurocrine Biosciences Inc | 5.04x | 28.59% | 98.17% | 2.31% | $160.19 |
| EXELExelixis Inc | 5.23x | 7.91% | 96.44% | 31.10% | $50.33 |
| KRYSKrystal Biotech, Inc. Common Stock | 21.92x | 25.15% | 94.17% | — | $313.68 |
| IBRXImmunityBio, Inc. Common Stock | 75.30x | 668.31% | 99.34% | — | $8.17 |
About
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.